496 related articles for article (PubMed ID: 31229934)
21. Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.
Baroncelli S; Pirillo MF; Galluzzo CM; Antoni AD; Ladisa N; Francisci D; d'Ettorre G; Segala D; Vivarelli A; Sozio F; Cirioni O; Weimer LE; Fragola V; Parruti G; Floridia M
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):71-7. PubMed ID: 25092266
[TBL] [Abstract][Full Text] [Related]
22. Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.
Watanabe D; Ibe S; Uehira T; Minami R; Sasakawa A; Yajima K; Yonemoto H; Bando H; Ogawa Y; Taniguchi T; Kasai D; Nishida Y; Yamamoto M; Kaneda T; Shirasaka T
BMC Infect Dis; 2011 May; 11():146. PubMed ID: 21605468
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.
Nicastri E; Palmisano L; Sarmati L; D'Ettorre G; Parisi S; Andreotti M; Buonomini A; Pirillo FM; Narciso P; Bellagamba R; Vullo V; Montano M; Di Perri G; Andreoni M
Curr HIV Res; 2008 May; 6(3):261-6. PubMed ID: 18473790
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
25. Slow or fast viral load decay as a predictor of residual viremia level in HIV-infected patients undergoing successful first-line cART.
Amendola A; Bibbolino G; Navarra A; Pisciotta M; Marsella P; Pinnetti C; Abbate I; Rozera G; Mondi A; Antinori A; Capobianchi MR; Girardi E; Ammassari A
New Microbiol; 2017 Oct; 40(4):234-241. PubMed ID: 29184963
[TBL] [Abstract][Full Text] [Related]
26. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 CRF01_AE subtype and HIV-1 DNA level among patients with chronic HIV-1 infection: a correlation study.
Lyu T; Yue Y; Hsieh E; Han Y; Zhu T; Song X; Cao W; Lyu W; Wang J; Li T
BMC Infect Dis; 2020 Jan; 20(1):66. PubMed ID: 31964364
[TBL] [Abstract][Full Text] [Related]
28. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
29. HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy.
Malagnino V; Cerva C; Maffongelli G; Teti E; Foroghi Biland L; Cesta N; De Masi M; Stingone C; Armenia D; Svicher V; Salpini R; Andreoni M; Sarmati L
Sci Rep; 2019 Aug; 9(1):11942. PubMed ID: 31420570
[TBL] [Abstract][Full Text] [Related]
30. Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients.
Chen S; Han Y; Song XJ; Li YL; Zhu T; Lu HZ; Tang XP; Zhang T; Zhao M; He Y; He SH; Wang M; Li YZ; Huang SB; Li Y; Liu J; Cao W; Li TS
Infect Dis Poverty; 2020 Jun; 9(1):75. PubMed ID: 32571409
[TBL] [Abstract][Full Text] [Related]
31. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
[TBL] [Abstract][Full Text] [Related]
32. Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy.
Blazkova J; Whitehead EJ; Schneck R; Shi V; Justement JS; Rai MA; Kennedy BD; Manning MR; Praiss L; Gittens K; Wender PA; Oguz C; Lack J; Moir S; Chun TW
J Infect Dis; 2024 Jun; 229(6):1770-1780. PubMed ID: 38128541
[TBL] [Abstract][Full Text] [Related]
33. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
[TBL] [Abstract][Full Text] [Related]
34. Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients.
Bon I; Calza L; Musumeci G; Longo S; Bertoldi A; D'Urbano V; Gibellini D; Magistrelli E; Viale PL; Re MC
Curr HIV Res; 2017; 15(6):448-455. PubMed ID: 29210661
[TBL] [Abstract][Full Text] [Related]
35. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
36. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
38. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
[TBL] [Abstract][Full Text] [Related]
39. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
[TBL] [Abstract][Full Text] [Related]
40. Comparative Analysis of Cell-Associated HIV DNA Levels in Cerebrospinal Fluid and Peripheral Blood by Droplet Digital PCR.
de Oliveira MF; Gianella S; Letendre S; Scheffler K; Kosakovsky Pond SL; Smith DM; Strain M; Ellis RJ
PLoS One; 2015; 10(10):e0139510. PubMed ID: 26431315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
